伯利兹治疗前及获得性HIV耐药性:2021-2022年全国代表性调查结果
2021至2022年在伯利兹开展全国代表性横断面调查,评估成人启动抗逆转录病毒治疗(ART)前的耐药率及接受ART者的病毒抑制和获得性耐药。成人治疗前对依非韦伦或奈韦拉平的耐药率为49.3%(95%CI 42.2%-56.4%),既往抗逆转录病毒暴露者耐药风险更高(OR 7.16;95%CI 2.71-18.95;P=0.002)。儿童青少年病毒抑制率50.0%,多替拉韦方案者抑制率更高(OR 5.31;95%CI 3.02-9.34;P<0.001),成人病毒抑制率79.6%,多替拉韦方案者未观察到整合酶抑制剂耐药。
要点
- 成人启动ART前对依非韦伦或奈韦拉平的耐药率为49.3%(95%CI 42.2%-56.4%)。
- 既往抗逆转录病毒暴露者治疗前耐药风险更高(OR 7.16;95%CI 2.71-18.95;P=0.002)。
- 多替拉韦方案者病毒抑制率更高,儿童青少年OR 5.31(95%CI 3.02-9.34;P<0.001)。
核心结论
- 优先使用基于多替拉韦的ART对伯利兹实现HIV流行控制至关重要,并应关注保留在护理和依从性支持以预防HIV耐药。
研究设计与样本
- 2021至2022年开展全国代表性横断面治疗前耐药和治疗后耐药调查,治疗前耐药调查纳入67名成人,获得性耐药调查纳入43名儿童青少年和331名成人,使用斯坦福HIVdb工具预测HIV耐药。
主要发现
- 成人治疗前对依非韦伦或奈韦拉平的耐药率为49.3%(95%CI 42.2%-56.4%),既往抗逆转录病毒暴露者耐药风险更高(OR 7.16;95%CI 2.71-18.95;P=0.002)。
- 接受ART的儿童青少年中50.0%获得病毒抑制,多替拉韦方案者抑制率更高(OR 5.31;95%CI 3.02-9.34;P<0.001)。
- 成人中79.6%获得病毒抑制。
- 使用多替拉韦方案者中未观察到整合酶抑制剂耐药。
关键数值与推荐
- 世界卫生组织(WHO)推荐基于多替拉韦的ART方案,因其耐药遗传屏障高且治疗结局更好,预期有助于实现联合国艾滋病规划署(UNAIDS)95%病毒抑制目标。
临床怎么用
- 作者认为优先使用基于多替拉韦的ART对伯利兹实现HIV流行控制至关重要。
- 作者建议努力聚焦于保留在护理和依从性支持以预防HIV耐药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rising prevalence of pretreatment drug resistance (PDR) to non-nucleoside reverse-transcriptase inhibitors threatens the effectiveness of ART. In response, the WHO recommends dolutegravir-based ART regimens due to their high genetic barrier to resistance and better treatment outcomes. This is expected to contribute to achieving the Joint United Nations Programme on HIV/AIDS (UNAIDS) target of 95% viral suppression in people on ART. OBJECTIVES: To estimate the prevalence of PDR among adults initiating ART and assess viral suppression and acquired HIV drug resistance (ADR) among individuals receiving ART in Belize. PATIENTS AND METHODS: Nationally representative cross-sectional PDR and ADR surveys were conducted between 2021 and 2022. Sixty-seven adults were included in the PDR survey, and 43 children and adolescents and 331 adults were included in the ADR survey. Demographic and clinic data and blood specimens were collected. HIV drug resistance (HIVDR) was predicted using the Stanford HIVdb tool. RESULTS: The prevalence of PDR to efavirenz or nevirapine in adults was 49.3% (95% CI 42.2%-56.4%) and was significantly higher in those with previous antiretroviral exposure (OR: 7.16; 95% CI 2.71-18.95; P = 0.002). Among children and adolescents receiving ART, 50.0% had viral suppression, with better rates for those receiving dolutegravir-based ART (OR: 5.31; 95% CI 3.02-9.34; P < 0.001). In adults, 79.6% achieved viral suppression. No resistance to integrase inhibitors was observed in those on dolutegravir-based ART. CONCLUSIONS: Prioritizing dolutegravir-based ART is critical for achieving HIV epidemic control in Belize. Efforts should focus on retention in care and adherence support to prevent HIVDR.
引用
- Morey F, Girón-Callejas A, Manzanero R, et al. Pretreatment and acquired HIV drug resistance in Belize-results of nationally representative surveys, 2021-22. J Antimicrob Chemother. 2025. PMID: 39556256. doi:10.1093/jac/dkae408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。